It is known that permanent inflammation comes along with the risk of cancer development, so that prophylaxis and interruption of inflammatory cascades, like targeting NF-κB signaling (Figure 1), are essential in cancer therapy, since genes regulated by NF-κB have been already shown to be involved carcinogenesis (68, 69). The gene discussed is NFKB1; the disease is cancer.